The antibiotics market will represent about 45 billion dollars in 2020 and with a growth rate of around 2% between 2015 and 2020. Antibiotics have significantly reduced the mortality associated with infectious diseases during the 20th century. Unfortunately, their massive and repeated use has led to the emergence of bacteria resistant to these drugs. These resistances, which were initially ad hoc, have become a cause for concern and lead to the need to develop new classes of antibiotics. 

This is the purpose of the SPARTBIOTICS project, which focuses on the development and validation of a new antimicrobial peptide targeting bacterial replication (via the ring β), particularly Gram-negative.